Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease (CKD), according to Spherix Global Insights.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...